Lindsay A. Rein, MD, reviews exciting data presented at this year’s ASH meeting, focusing on chronic myeloid leukemia (CML) and the recent approval of asciminib, a novel agent for first-, second-, and third-line treatment of CML. Key updates included results from the phase 3 ASC4FIRST trial, which showed that asciminib provided superior efficacy in achieving major and deep molecular responses compared with other tyrosine kinase inhibitors, with favorable safety and tolerability.
Dr Rein also notes the ongoing need for new therapies for patients who are intolerant of or refractory to standard treatments, and the importance of defining treatment resistance and intolerance in CML. Patient-centered outcomes such as quality of life and treatment costs were emphasized, with presentations exploring how treatment adjustments could improve these factors. Finally, discussions on CML mutations and treatment of advanced stages of the disease, such as blast crisis, highlighted continuing unmet medical needs in this disease.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2024: Key Highlights in the Research and Treatment of CML - Medscape - Dec 16, 2024.
Comments